The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients

The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients

We investigated the potential differential effects of antiretroviral therapies on unbalanced chemokine homeostasis and on the progression of atherosclerosis in HIV-infected patients. A two-year prospective study was performed in 67 consecutive HIV-infected patients initiating antiretroviral therapy...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gerard Aragonès, Pedro Pardo-Reche, Laura Fernández-Sender, Anna Rull, Raúl Beltrán-Debón, Esther Rodríguez-Gallego, Jordi Camps, Jorge Joven, Carlos Alonso-Villaverde
Format:	Article
Language:	English
Published:	Wiley 2012-01-01
Series:	Mediators of Inflammation
Online Access:	http://dx.doi.org/10.1155/2012/372305
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ubiquitous Transgenic Overexpression of C-C Chemokine Ligand 2: A Model to Assess the Combined Effect of High Energy Intake and Continuous Low-Grade Inflammation
by: Esther Rodríguez-Gallego, et al.
Published: (2013-01-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

DELETERIOUS EFFECTS OF THE INFORMAL ECONOMY
by: N. Drozd
Published: (2014-01-01)

The role of the interactome in the maintenance of deleterious variability in human populations
by: Luz Garcia‐Alonso, et al.
Published: (2014-09-01)

Evaluation of cytokine levels in HIV-infected individuals on therapy with tenofovir, lamivudine, and dolutegravir
by: C.D. da Silva-Junior, et al.
Published: (2025-05-01)

Synthesis and Evaluation of Anti-HIV Activity of Mono- and Di-Substituted Phosphonamidate Conjugates of Tenofovir
by: Aaminat Qureshi, et al.
Published: (2022-07-01)

The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity.
by: Karen Klassen, et al.
Published: (2012-01-01)

Tenofovir Nephrotoxicity: 2011 Update
by: Beatriz Fernandez-Fernandez, et al.
Published: (2011-01-01)

Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
by: Huw Price, et al.
Published: (2013-01-01)

Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01)

Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
by: Eric S. Daar, et al.
Published: (2025-04-01)

Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)
by: Roberta Gagliardini, et al.
Published: (2025-09-01)

Deleterious Effect of Fructose on the Heart Function of Hypertriglyceridemic Rats
by: Vladimír Knezl, et al.
Published: (2025-04-01)

Deleterious effect of Usutu virus on human neural cells.
by: Sara Salinas, et al.
Published: (2017-09-01)

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate
by: Derek E. Murrell, et al.
Published: (2025-05-01)

Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
by: Shenglong Lin, et al.
Published: (2024-11-01)

Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States
by: Bruno Emond, et al.
Published: (2022-02-01)

Deleterious effects of thermal and water stresses on life history and physiology: a case study on woodlouse
by: Depeux, Charlotte, et al.
Published: (2023-01-01)

IL-17 can be protective or deleterious in murine pneumococcal pneumonia.
by: Neil D Ritchie, et al.
Published: (2018-05-01)

Screening and Evaluation of Deleterious SNPs in APOE Gene of Alzheimer’s Disease
by: Tariq Ahmad Masoodi, et al.
Published: (2012-01-01)

Rise and fall of deleterious variants: the origins of modern genetic diseases
by: Brina López Gfeller, et al.
Published: (2021-12-01)

Health Economics Evaluation of Bictegravir/Emtricitabine/Tenofovir for a First-Line Treatment of HIV-1 Infection in China
by: Wang W, et al.
Published: (2025-05-01)

Renal Outcomes Over the Course of 5 Years of Oral HIV Preexposure Prophylaxis Using Tenofovir Disoproxil/Emtricitabine
by: Dita C. Bolluyt, et al.
Published: (2025-06-01)

Factors Affecting Rapid Decline in Glomerular Filtration Rate in HIV/AIDS Patients Using Tenofovir Disoproxil Fumarate
by: Prima Yuriandro, et al.
Published: (2019-09-01)

Metabolic Reprogramming in Respiratory Viral Infections: A Focus on SARS-CoV-2, Influenza, and Respiratory Syncytial Virus
by: Jordi Camps, et al.
Published: (2025-07-01)

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
by: Ping‐Feng Wu, et al.
Published: (2024-12-01)

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate
by: Hamed Mirmoezzi, et al.
Published: (2025-03-01)

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
by: Diana M Gibb, et al.
Published: (2012-01-01)

Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.
by: Freeman W Chabala, et al.
Published: (2021-01-01)

Health care providers' decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study.
by: Elisabeth Merchant, et al.
Published: (2024-01-01)

In‐utero exposure to tenofovir‐containing pre‐exposure prophylaxis and bone mineral content in HIV‐unexposed infants in South Africa
by: Kerusha Reddy, et al.
Published: (2024-11-01)

Urine tenofovir adherence testing: Perspectives of recently diagnosed South African adolescents and young adults with HIV accessing care via mobile HIV clinics.
by: Michalina A Montaño, et al.
Published: (2025-01-01)

Scrutinizing Deleterious Nonsynonymous SNPs and Their Effect on Human POLD1 Gene
by: Md. Nazmul Islam Bappy, et al.
Published: (2022-01-01)

Epileptic Encephalopathy Related to CAD Deleterious Variants—A Case Series
by: Adelina Glangher, et al.
Published: (2025-03-01)

Computational prediction of deleterious nonsynonymous SNPs in the CTNS gene: implications for cystinosis
by: Leila Adda Neggaz, et al.
Published: (2025-05-01)

Structural and deleterious burdens and their effects on yield traits in foxtail millet domestication
by: Mengrui Du, et al.
Published: (2025-09-01)

Allelic expression of deleterious protein-coding variants across human tissues.
by: Kimberly R Kukurba, et al.
Published: (2014-05-01)

Renal Concerns in the Treatment of Chronic Hepatitis B with Tenofovir
by: Giuseppe Coppolino, et al.
Published: (2017-03-01)

Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
by: Rashmee Patil, et al.
Published: (2015-01-01)

Novel Micro-LC-MS/MS Method for the Quantification of Tenofovir and Its Active Metabolite Tenofovir-Diphosphate in Biological Matrices for Therapeutic Drug Monitoring
by: Isabela Tarcomnicu, et al.
Published: (2025-06-01)